Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey

Advances in Therapy

Volumn 29, Issue 1, 2012, Pages 41-52

  Prymula, Roman ^a   Usluer, Gaye ^b   Altinel, Serdar ^c   Sichova, Radka ^d   Weber, Françoise ^e  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^c Sanofi Pasteur   (Turkey)

^d Sanofi Pasteur   (Czech Republic)

^e SANOFI PASTEUR   (France)

Author keywords

acceptability; influenza; Intanza IDflu; intradermal; seasonal; trivalentinactivated; vaccine; vaccinee satisfaction

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CZECH REPUBLIC; FEMALE; HEALTH SURVEY; HUMAN; INFLUENZA VACCINATION; INJECTION PAIN; MALE; NORTHERN HEMISPHERE; PATIENT ATTITUDE; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; QUESTIONNAIRE; SEASONAL INFLUENZA; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; ATTITUDE TO HEALTH; CZECH REPUBLIC; FEMALE; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; ORTHOMYXOVIRIDAE; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SATISFACTION; PUBLIC HEALTH; QUESTIONNAIRES; TURKEY;

EID: 84857906660     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0090-5     Document Type: Article

References (28)

1. Monto AS. Seasonal influenza and vaccination coverage. Vaccine. 2010;28(suppl. 4):D33-D44.
2. World Health Organization. Influenza (seasonal). Available at: http://www.who.int/mediacentre/factsheets/fs211/en/index.html. Accessed October 6, 2011.
3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. (Pubitemid 36068705)
4. Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283:499-505. (Pubitemid 30062866)
5. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health. 1986;76:761-765. (Pubitemid 16060716)
6. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 1980;112:798-811.
7. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086-5096. (Pubitemid 46879994)
8. Xue Y, Kristiansen IS, de Blasio BF. Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave. BMC Public Health. 2010;10:724.
9. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995;333:889-893.
10. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655-1663.
11. World Health Organization. Resolution of the World Health Assembly WHA 56.19. Prevention and control of influenza pandemics and annual epidemics. 56th World Health Assembly, Geneva 2003.
12. The Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. Official Journal of the European Union. 2009;L348:71-72.
13. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1-62.
14. Centers for Disease Control. Healthy People 2020 Summary of Objectives. Available at: http://healthypeople.gov/2020/topicsobjectives2020/pdfs/ Immunization.pdf. Accessed March 7, 2011.
15. Centers for Disease Control and Prevention. Interim results: state-specific seasonal influenza vaccination coverage - United States, August 2009-January 2010. MMWR Morb Mortal Wkly Rep. 2010;59:477-484.
16. Prausnitz MR, Mikszta JA, Cormier M, et al. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009;333:369-393.
17. Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine. 2007;25:8833-8842. (Pubitemid 350192056)
18. European Medicines Agency. Assessment report for Intanza®. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000957/human-med-000842.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d125&jsenabled=true. Accessed December 2, 2011.
19. Arnou R, Eavis P, Pardo JR, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin. 2010;6:346-354.
20. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009;27:7304-7312.
21. Beran J, Ambrozaitis A, Laiskonis A, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 2009;7:13.
22. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198:650-658.
23. Leroux-Roels I, Vets E, Freese R, et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine. 2008;26:6614-6619.
24. Güvenlik Kurumu Saslik Uygulama Talimati. Directive for Practice of Health. Available at: http://www.sgk.gov.tr/wps/portal/ESGK/GSS. Accessed December 2, 2011.
25. Blank PR, Szucs TD. Increasing influenza vaccination coverage in recommended population groups in Europe. Expert Rev Vaccines. 2009;8:425-433.
26. Eizenberg P, Booy R, Naser N, et al. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther. 2011;28:640-649.
27. Reygrobellet C, Viala-Danten M, Meunier J, et al. Perception and acceptance of intradermal influenza vaccination: patient reported outcomes from phase 3 clinical trials. Hum Vaccin. 2010;6:336-345.
28. Arnou R, Frank M, Hagel T, et al. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany. Adv Ther. 2011;28:555-565.